Benfotiamine

Catalog No.S4798 Batch:S479803

Print

Technical Data

Formula

C19H23N4O6PS

Molecular Weight 466.45 CAS No. 22457-89-2
Solubility (25°C)* In vitro 5%TFA 6 mg/mL (12.86 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Biological Activity

Description Benfotiamine (S-Benzoylthiamine O-monophosphate) is a synthetic S-acyl derivative of thiamine (vitamin B1) and has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2. Benfotiamine suppresses oxidative stress-induced NF-κB activation and prevents the bacterial endotoxin-induced inflammation.
Targets
NF-κB [4]
In vitro

Benfotiamine improves the expression of endothelial cell markers in EPCs, restores eNOS levels, and recovers the ability of EPCs to participate in angiogenic processes. It is able to dampen glucose toxicity effects on endothelial progenitors[1]. Benfotiamine possesses antitumor activity against leukemia cells. In a panel of nine myeloid leukemia cell lines benfotiamine impairs the viability of HL-60, NB4, K562 and KG1 cells and also inhibits the growing of primary leukemic blasts. The antitumor activity of benfotiamine is not mediated by apoptosis, necrosis or autophagy, but rather occurs though paraptosis cell death induction. Benfotiamine inhibits the activity of constitutively active ERK1/2 and concomitantly increases the phosphorylation of JNK1/2 kinase in leukemic cells. In addition, benfotiamine induces the down regulation of the cell cycle regulator CDK3 which results in G1 cell cycle arrest in the sensitive leukemic cells[2].

In vivo

Benfotiamine might exert vascular and renal benefits by modulating mechanisms independent or downstream of ROS formation. Benfotiamine aids the post-ischaemic healing of diabetic animals via PKB/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis[3].

Protocol (from reference)

Cell Assay:

[2]

  • Cell lines

    leukemia cells (HL60, AML 1, NB4 cells)

  • Concentrations

    50 μM

  • Incubation Time

    24, 48, 72, 96 h

  • Method

    Cell viability is assessed using a colorimetric MTT metabolic activity assay.

Animal Study:

[3]

  • Animal Models

    diabetic animal model induced by STZ (male CD1 mice)

  • Dosages

    80 mg/kg

  • Administration

    oral administration

Selleck's Benfotiamine has been cited by 1 publication

Repurposing the natural compounds as potential therapeutic agents for COVID-19 based on the molecular docking study of the main protease and the receptor-binding domain of spike protein [ J Mol Model, 2022, 28(6):153] PubMed: 35578055

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.